Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Los Bonos 1 (no aplicable en España), 2 (Marcas y Diseños) y 3 (patentes nacionales, patentes europeas, informes tecnológicos de patentes y búsquedas retrospectivas) se encuentran cerrados desde el 20/08/2025. La solicitud del Bono 4 sigue abierta. Más adelante se informará sobre la reapertura de estos Bonos
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
122
resultados
Última actualización
31/08/2025 [07:25:00]
Resultados 25 a 50 de 122
Resumen de: AU2024220263A1
Provided herein are compounds, pharmaceutical compositions, and methods of use for selectively reducing the amount or activity of HTT RNA comprising SNP rs7685686 in a cell or subject, and in certain instances reducing the amount of mutant HTT protein in a cell or subject. Such compounds, pharmaceutical compositions, and methods of use are useful to ameliorate at least one symptom or hallmark of Huntington's disease.
Resumen de: WO2025172592A1
The present invention relates to immunogenic compositions that can be employed for the prevention, alleviation or treatment of a condition associated with diseases, disorders and abnormalities associated with alpha synuclein (alpha synuclein, α-synuclein, A-synuclein, aSynuclein, A-syn, α-syn, aSyn, a-syn) aggregates including, but not limited to, Lewy bodies and/or Lewy neurites, such as Parkinson's disease, Multiple System Atrophy, Lewy Body dementia (LBD; dementia with Lewy bodies (DLB) ("pure" Lewy body dementia), Parkinson's disease dementia (PDD)), or Diffuse Lewy Body Disease.
Resumen de: WO2025171484A1
Disclosed herein are sublingual formulations of fasudil and methods for using the same to treat neurological conditions such as ALS.
Resumen de: WO2025173839A1
The present invention relates to: an albumin-immobilized cellulose; and a composition for treating Alzheimer's disease, the composition comprising the albumin-immobilized cellulose. More specifically, the present invention relates to an albumin (human serum albumin, HSA)-immobilized cellulose having excellent amyloid beta (Aβ) adsorption capacity, and a composition for treating Alzheimer's disease by using an in vitro amyloid beta (Aβ) trap, wherein the composition comprises the albumin-immobilized cellulose.
Resumen de: WO2025175135A1
Provided herein are compositions and methods of treating and/or preventing Parkinson's Disease (PD) in a subject in need thereof, the methods including administering an agent that increases, enhances, and/or stimulates Kcnn1 expression or activity.
Resumen de: US2025262260A1
The present disclosure provides use of a turnip extract in the preparation of a drug for the prevention and treatment of Alzheimer's disease, which belongs to the technical field of biomedicine. The turnip extract of the present disclosure has good activity against Alzheimer's disease and has good application prospects in a drug for the prevention and treatment of Alzheimer's disease.
Resumen de: US2025262230A1
As described herein, inhibitors of High mobility group box protein 1 (HMGB1) can significantly reduce HMGB1 nucleo-cytoplasmic translocation, gliosis, neurodegeneration, Tau pathologies, and myelin deficits, especially in subjects having an AP0E4 allele. Methods are therefore described herein that include administering one or more inhibitors of High mobility group box protein 1 (HMGB1) to a subject having at least one genomic AP0E4 allele.
Resumen de: US2025263412A1
This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a heteroaryl substituted oxadiazole structure which function as non-hydroxamate histone deacetylase 6 (HDAC6) inhibitors, and their use as therapeutics for the treatment of metabolic disorders (e.g., obesity, Diabetes), neurological disorders (e.g., Alzheimer's disease, Parkinson disease, Huntington disease), cancer (e.g., multiple myeloma, biliary tract cancer, non-small cell lung cancer, chronic lymphocytic leukemia) and other conditions related to HDAC6 activity (e.g., Rett syndrome (RTT), inherited retinal disorders (IRDS), idiopathic pulmonary fibrosis (IPF), and Charcot-Marie-Tooth disease (CMT)).
Resumen de: AU2023358527A1
Described herein are methods and compositions for treating Alzheimer's Disease (AD), as well as compositions comprising a reelin-derived peptide and methods of use thereof.
Resumen de: WO2025171411A1
The present disclosure provides methods for preventing, treating, or delaying progression of neuroinflammatory CNS conditions, e.g., Alzheimer's disease, by administration of an agent that inhibits macrophage migration inhibitory factor (MIF)-CD74 signaling. In some embodiments the agent to be administered is a MIF-binding protein such as a MIF antibody. In other embodiments disclosed herein the agent is a targeting polynucleotide against MIF or CD74.
Resumen de: WO2025168003A1
Provided are a pharmaceutical composition for preventing and/or treating neurodegenerative diseases and use thereof. The pharmaceutical composition comprises rivastigmine, liraglutide, and derivatives thereof; the pharmaceutical composition further comprises a sustained-release system, the sustained-release system can interact with the rivastigmine, the liraglutide, and the derivatives thereof to form a copolymer that enables sustained drug release, and the sustained-release system is a triblock hydrogel sustained-release system. The combination of the liraglutide and the rivastigmine can ameliorate the learning and memory impairments associated with Alzheimer's disease, with the effect superior to monotherapy and exhibiting a synergistic effect.
Resumen de: US2025257124A1
The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.
Resumen de: US2025255903A1
Provided herein is a method for treating Parkinson's disease (PD). The method can include identifying a subject and treating the subject with expanded natural killer cells (NKs). Also provided is a composition for treating PD.
Resumen de: US2025255856A1
Compositions herein disclosed are conceived for the treatment and prevention of diseases caused by accumulation of heparan sulfate including mucopolysaccharidosis, Alzheimer's disease and cancers. These compositions include as active ingredient an iminosugar belonging to L-steric series and derivatives thereof. The L-iminosugars of this invention are able to reduce the levels of heparan sulfate in cells of patients affected by mucopolysaccharidosis and cancer, and to reduce the accumulation of amyloid plaques in a model of neurodegenerative disease. Therefore, the use of these compounds prevents the onset of symptoms associated with these diseases, thus improving the quality and length of life of patients suffering from diseases characterized by accumulation of heparan sulfate.
Resumen de: WO2024184305A1
Compounds (I) are provided, where R1 and R2 are H or (C1-C3)-alkyl; X is a linear methylene chain of formula -CH2n- with n = 0, 1 or 2, or a biradical from a branched saturated (C2-C4)-alkylene chain; and A is either a C-radical from a non-aromatic polycyclic 6- to 15-membered carbocyclic ring system, or a C-radical from a polycyclic 6- to 15-membered heterocyclic ring system having one or two O, S or N; wherein the C-radicals are unsubstituted or substituted. Compounds (I) are simultaneously inhibitors of soluble epoxide hydrolase and inhibitors of glutaminyl cyclase. Besides, they reduce the levels of pro-inflammatory cytokines in LPS stimulated BV2 cells, display low cytotoxicity, and have good BBB permeability. Thus, they are useful as multitarget compounds for the prevention or treatment of Alzheimer's disease.
Resumen de: EP4599838A1
The objective of the present invention is to provide an Alzheimer-type dementia suppressant that is safe and thus can be administered daily and utilized as a health food and by which Alzheimer-type dementia can be suppressed, and a method for producing the Alzheimer-type dementia suppressant. In addition, the objective of the present invention is also to provide a use of an aboveground part of Sesamum indicum or an extract thereof for suppressing Alzheimer-type dementia, and a method for suppressing Alzheimer-type dementia. The Alzheimer-type dementia suppressant according to the present invention is characterized in comprising an aboveground part of Sesamum indicum or an extract thereof as an active ingredient.
Resumen de: EP4599696A2
This invention relates to the delivery of a composition, preferably a pharmaceutical composition, comprising D-pinitol, D-Chiro inositol or myo-inositol or any pharmaceutically acceptable salt thereof, for use in the treatment or prevention of disorders, diseases or conditions responsive to the stimulation of the ghrelin receptor in a subject in need thereof. In particular, for the treatment and/or prevention of disorders responsive to the positive modulation (stimulation) of the ghrelin receptor, such as diabetes, obesity-related disorders, and, most preferably, for treating or preventing age related conditions or diseases such as by promoting appetite, inhibiting insulin secretion and lowering insulin resistance, increasing growth hormone release, enhancing muscle vitality or fragility and treating or preventing sarcopenia by increasing net muscle mass, improving cognition (and/or treating or preventing diseases such as Azlheimer's disease, vascular dementia, Parkinson's Disease, and Huntington's disease) and treating or preventing age related hypertension.
Resumen de: GR20240100037A
The invented natural plant-based food supplement capsules are designed for the management of individuals suffering from memory impairment, mild cognitive impairment, or from early-stage Alzheimer's and Parkinson's disease. The natural plant-origin ingredients contained in the capsule are a combination of antioxidants offering better antioxidant, anti-apoptotic, and neuroprotective action; they penetrate the blood-brain barrier, acting on the neurons of the brain, and they inhibit the formation of amyloid-b proteins and Tau protein which are involved in neurodegenerative disorders, inhibitingthe progression and worsening of Alzheimer's and Parkinson's disease. Said capsules are designed for people wishing to take natural plant-origin products. Compared to the side effects of existing formulations, said capsules exhibit minimal side effects.
Resumen de: WO2025162734A1
The present invention relates to a food- or feedstuff composition comprising a B. subtilis strain and a Ginkgo biloba extract, such composition for use as a medicament as well as such composition for use in treating or preventing neurodegenerative diseases, in particular Alzheimer's disease as well as the use of such composition as a food supplement.
Resumen de: AU2025205635A1
This invention provides with an edaravone suspension for oral administration having excellent bioavailability. It is expected that burden on ALS patients and care workers can be reduced thereby. This invention provides with an edaravone suspension for oral administration having excellent bioavailability. It is expected that burden on ALS patients and care workers can be reduced thereby. ul h i s i n v e n t i o n p r o v i d e s w i t h a n e d a r a v o n e s u s p e n s i o n f o r o r a l a d m i n i s t r a t i o n h a v i n g e x c e l l e n t u l b i o a v a i l a b i l i t y t i s e x p e c t e d t h a t b u r d e n o n p a t i e n t s a n d c a r e w o r k e r s c a n b e r e d u c e d t h e r e b y
Resumen de: AU2025205501A1
18808542_1 (GHMatters) P43228AU01 Provided herein are RNAi molecules including a first strand containing a guide sequence and a second strand comprising a non-guide sequence where the non-guide sequence contains a bulge opposite the seed region of the guide sequences; e.g., opposite the cleavage sequence. In some aspects, the invention provides RNAi for treating Huntington’s disease. Further provided herein are expression cassettes, vectors (e.g., rAAV, recombinant adenoviral, recombinant lentiviral, and recombinant HSV vectors), cells, viral particles, and pharmaceutical compositions containing the RNAi. Yet further provided herein are methods and kits related to the use of the RNAi, for example, to treat Huntington’s disease. Provided herein are RNAi molecules including a first strand containing a guide sequence and a second strand comprising a non-guide sequence where the non-guide sequence contains a bulge opposite the seed region of the guide sequences; e.g., opposite the cleavage sequence. In some aspects, the invention provides RNAi for treating Huntington's disease. Further provided herein are expression cassettes, vectors (e.g., rAAV, recombinant adenoviral, recombinant lentiviral, and recombinant HSV vectors), cells, viral particles, and pharmaceutical compositions containing the RNAi. Yet further provided herein are methods and kits related to the use of the RNAi, for example, to treat Huntington's disease. 18808542_1 (GHMatters) P43228AU01 ul u l r o v i d e d
Resumen de: WO2025163129A1
The present disclosure provides for treating Parkinson ́s disease (PD) comprising administering acetyl-leucine or a pharmaceutically acceptable salt thereof to a subject in need thereof.
Resumen de: US2025248960A1
The present invention provides methods of providing rapid relief of motor fluctuations in a Parkinson's disease patient. The methods of the invention comprise pulmonary administration of levodopa by inhalation at therapeutically effective concentrations such that the patient's plasma levodopa concentration increases by at least about 200 ng/ml within 10 minutes or less post inhalation as compared to the concentration of levodopa in the patient's plasma prior to inhalation of the levodopa and wherein the patient's plasma concentration remains increased by at least about 200 ng/ml for a time period of at least 15 minutes after inhalation. The methods of the invention are particularly useful for treatment of motor fluctuations which arise as a result of poorly controlled levodopa plasma levels in a patient.
Resumen de: US2025250324A1
A fusion protein of the present disclosure may induce the degradation of neurodegenerative disease-causing factors by binding to Tau and amyloid-beta proteins as the neurodegenerative disease-causing factors and activating autophagy. In addition, the fusion protein of the present disclosure penetrates a blood-brain barrier and is introduced into cells to be effectively delivered into nerve cells without a separate carrier, and has high stability and thus is expected to be used as a platform for the treatment of neurodegenerative diseases such as dementia and Alzheimer's disease.
Nº publicación: US2025248985A1 07/08/2025
Solicitante:
VANDA PHARMACEUTICALS INC [US]
VANDA PHARMACEUTICALS INC
Resumen de: US2025248985A1
The invention relates generally to the treatment of Parkinson's Disease (PD), including Parkinson's Disease psychosis (PDP) with iloperidone.
BOPI
Sede Electrónica
